NCT00352365 2022-02-11
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
13 trialsNCT02472691 2020-05-28
AZALENA
Heinrich-Heine University, Duesseldorf
Phase 2 Completed
NCT02538965 2020-01-07
A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Celgene
Phase 2 Completed
NCT01743859 2019-10-08
Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
University of Colorado, Denver
Phase 2 Completed
NCT01358734 2019-06-25
A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia
Celgene
Phase 2 Completed
NCT01442714 2018-01-03
Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS
Stanford University
Phase 2 Terminated
NCT01301820 2016-03-16
Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)
French Innovative Leukemia Organisation
Phase 2 Completed
NCT00957385 2015-06-19
Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients
University Health Network, Toronto
Phase 2 Completed
NCT00885508 2015-04-24
GFM-Chimio-Rev
Groupe Francophone des Myelodysplasies
Phase 2 Unknown
NCT00546897 2014-09-29
Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities
Washington University School of Medicine
Phase 2 Completed
NCT00720850 2013-09-27
LENAMAINT
Technische Universität Dresden
Phase 2 Terminated
NCT00360672 2013-08-14
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01556477 2012-03-16
The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).
Nordic MDS Group
Phase 2 Unknown